-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the continuous growth of the number of cancer patients in China, the continuous improvement of the medical level, and the continuous upgrading of consumption, the domestic market demand for anti-tumor drugs is constantly growing
.
It is worth noting that the huge market prospects are naturally attracting more and more pharmaceutical companies to enter the market
.
According to data, among the 154 PD-1s currently under research in the world, 85 are developed or jointly developed by Chinese companies, accounting for 55%
.
Of course, with the increasing number of companies entering the game, new achievements in this field are also emerging
.
It is understood that in recent years, with the support of a series of favorable policies, the innovation and research and development capabilities of domestic pharmaceutical companies for oncology drugs have been continuously improved, and they are already in a period of rapid growth
.
At the same time, more and more pharmaceutical companies have received good news in the field of anti-tumor drug innovation
.
For example, recently, Junshi Biosciences and Coherus BioSciences jointly announced that the two parties will expand the cooperation in the field of tumor immunity reached in 2021.
Coherus has started to exercise the license option of JS006 (anti-TIGIT monoclonal antibody independently developed by Junshi Biosciences) in the United States and Canada.
rights procedure
.
According to the announcement, Coherus will pay Junshi Biotechnology an upfront payment of $35 million, development, filing and sales milestone payments of up to $255 million, as well as an 18% sales share of net product sales
.
The transaction is expected to be completed following the completion of government formalities required by applicable law
.
On January 11, Shenzhen Xinhe Biomedical Technology Co.
, Ltd.
(abbreviation: Xinhe Bio), an RNA drug research and development company, and PhoreMost Limited (referred to as PhoreMost), a British biopharmaceutical company dedicated to non-drugable target drugs, also jointly announced: Signed a research and development cooperation agreement on the use of PhoreMost's SITESEEKER technology platform and Xinhe Bio's RNA drug design platform to jointly carry out innovative therapeutic research on anti-tumor drugs
.
It is understood that PhoreMost's SITESEEKER technology platform can discover new targets for any disease and quickly determine how to develop new drugs against these targets
.
In this cooperation, the two parties will use PhoreMost's SITESEEKER phenotype screening platform and Xinhe Bio's full-process RNA drug design platform to explore the cellular delivery and efficacy of encoded target polypeptides to promote the research and development of new anti-tumor therapies
.
In addition to the above companies, according to incomplete statistics, anti-tumor drugs accounted for more than half of the more than 700 new clinical drugs approved in China last year, involving pharmaceutical companies such as Hengrui and Junshi
.
In this context, the industry expects that new domestic anti-tumor drugs will usher in a big outbreak
.
However, it should be noted that there is a serious problem of homogenization and competition in China's drug research and development.
New drug research and development presents the characteristics of me too and me follow-based research far more than first in class or best in class research
.
Among them, the same is true in the field of antitumor drugs
.
To this end, on November 19 last year, the Center for Drug Evaluation (CDE) of the State Drug Administration officially issued the "Guidelines for Clinical Research and Development of Antitumor Drugs Oriented to Clinical Value".
In the context of the further improvement of the requirements for high efficiency, high quality and high safety in research and development, those new drugs with low clinical value will be returned or the approval difficulty will be increased, and relevant enterprises will face more challenges in research and development innovation
.
.
It is worth noting that the huge market prospects are naturally attracting more and more pharmaceutical companies to enter the market
.
According to data, among the 154 PD-1s currently under research in the world, 85 are developed or jointly developed by Chinese companies, accounting for 55%
.
Of course, with the increasing number of companies entering the game, new achievements in this field are also emerging
.
It is understood that in recent years, with the support of a series of favorable policies, the innovation and research and development capabilities of domestic pharmaceutical companies for oncology drugs have been continuously improved, and they are already in a period of rapid growth
.
At the same time, more and more pharmaceutical companies have received good news in the field of anti-tumor drug innovation
.
For example, recently, Junshi Biosciences and Coherus BioSciences jointly announced that the two parties will expand the cooperation in the field of tumor immunity reached in 2021.
Coherus has started to exercise the license option of JS006 (anti-TIGIT monoclonal antibody independently developed by Junshi Biosciences) in the United States and Canada.
rights procedure
.
According to the announcement, Coherus will pay Junshi Biotechnology an upfront payment of $35 million, development, filing and sales milestone payments of up to $255 million, as well as an 18% sales share of net product sales
.
The transaction is expected to be completed following the completion of government formalities required by applicable law
.
On January 11, Shenzhen Xinhe Biomedical Technology Co.
, Ltd.
(abbreviation: Xinhe Bio), an RNA drug research and development company, and PhoreMost Limited (referred to as PhoreMost), a British biopharmaceutical company dedicated to non-drugable target drugs, also jointly announced: Signed a research and development cooperation agreement on the use of PhoreMost's SITESEEKER technology platform and Xinhe Bio's RNA drug design platform to jointly carry out innovative therapeutic research on anti-tumor drugs
.
It is understood that PhoreMost's SITESEEKER technology platform can discover new targets for any disease and quickly determine how to develop new drugs against these targets
.
In this cooperation, the two parties will use PhoreMost's SITESEEKER phenotype screening platform and Xinhe Bio's full-process RNA drug design platform to explore the cellular delivery and efficacy of encoded target polypeptides to promote the research and development of new anti-tumor therapies
.
In addition to the above companies, according to incomplete statistics, anti-tumor drugs accounted for more than half of the more than 700 new clinical drugs approved in China last year, involving pharmaceutical companies such as Hengrui and Junshi
.
In this context, the industry expects that new domestic anti-tumor drugs will usher in a big outbreak
.
However, it should be noted that there is a serious problem of homogenization and competition in China's drug research and development.
New drug research and development presents the characteristics of me too and me follow-based research far more than first in class or best in class research
.
Among them, the same is true in the field of antitumor drugs
.
To this end, on November 19 last year, the Center for Drug Evaluation (CDE) of the State Drug Administration officially issued the "Guidelines for Clinical Research and Development of Antitumor Drugs Oriented to Clinical Value".
In the context of the further improvement of the requirements for high efficiency, high quality and high safety in research and development, those new drugs with low clinical value will be returned or the approval difficulty will be increased, and relevant enterprises will face more challenges in research and development innovation
.
